Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID

83% of Respondents With Acute COVID Were Satisfied

68% of Respondents With Long COVID Were Satisfied

NEW YORK, NY, and TEL AVIV, ISRAEL, June 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTC-BB:TOMDF), a comprehensive medical diagnostics and related solutions company, today announced preliminary data from its majority-owned joint venture 3CL Pharma Ltd.’s ongoing IRB-waived sponsored market research study of the commercial use of Tollovid® as a dietary supplement. Among the first 41 respondents, of whom 78% were fully vaccinated against COVID-19, 13 reported that they began to use Tollovid when they were diagnosed with active COVID infection, whereas 28 respondents reported that they used Tollovid to address their Long COVID symptoms. 15 of the Long COVID respondents had experienced symptoms for up to 9 months (‘Short’ Long COVID), and 12 of the Long COVID respondents reported having symptoms for over 9 months (‘Chronic’ Long COVID). 18 of the 24 respondents who answered the question “Who diagnosed your Long COVID?” indicated that they were diagnosed by a medical professional. The preliminary results of the market research study are marked in the table below: